Strategic partnerships LevitiasBio has recently announced collaborations with Cytiva and Planet Innovation to advance single-cell workflows and LeviCell EOS systems, signaling an openness to co-development and OEM/technology transfer opportunities that could expand partner channels and accelerate joint go-to-market efforts.

High-throughput focus The launch of LeviCell EOS for higher throughput cell isolation indicates a market push toward scalable sample processing; sales conversations can target labs and CROs requiring faster, preserved-cell workflows, offering them a path to increased throughput without compromising cell integrity.

Immunology expansion With LeviSelect depletion and enrichment kits for immunology research, there is a clear use-case expansion into immune profiling and antibody discovery, suggesting upsell opportunities for kit bundles, services, and ongoing assay development support.

End-to-end value LevitasBio positions itself as an end-to-end provider of sample processing and analysis; this can be leveraged to cross-sell hardware, consumables, and analytics services to labs seeking turnkey solutions rather than point solutions.

Strategic financing signals Recent Series C funding and leadership hires indicate growing credibility and capacity; this can be used to frame long-term collaboration discussions, available funding for pilot programs, and confidence-building proposals for large-scale DTC or academic partnerships.